October 2024 Content Release Copied

10/24/20242024 ContentContent releasePhysician, Clinical, Admin, Billing

Clinical Profile Documentation

Problem Groups

Additions

The Problems > Add Details area is updated with applicable documentation points for the following diagnoses.

HER2 by IHC was updated for Biliary Tract Cancers, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Head and Neck Cancer, Melanoma, Lung Cancer, Non-small Cell (NSCLC), Ovarian and Primary Peritoneal Cancer, Pancreatic Cancer, Rectal Cancer, and Uterine Cancer with the following documentation points:

3+
2+
1+
0
Unknown

HER2 by ISH was updated for Breast Cancer with the following documentation points:

Positive
Negative
Unknown

HER2 by ISH or NGS is now available for Biliary Tract Cancers, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Rectal Cancer, and Uterine Cancer with the following documentation points:

Positive
Negative
Unknown

HER2 status was updated for Breast Cancer with the following documentation points:

Positive: IHC 3+ or IHC 2+/ISH-positive
Low: IHC 1+ or IHC 2+/ISH-negative
Negative: IHC 0
Unknown

Problems

Additions

New items are available for documentation in Problems and appear in the Charge Capture Report (CCR). Additional ICD-10 codes may be displayed to present the surrounding nodes.

Please see APPENDIX A below for a complete summary of changes.

Lab Analytes & Panels

Analyte Additions

CYP2C cluster geno
CYP2C cluster pheno
CYP2C9 genotype
CYP2C9 phenotype
CYP4F2 genotype
CYP4F2 phenotype
HBV genotype + drug resistance
LDL calculation comment
Total cells counted, CSF
VKORC1 phenotype
West Nile virus IgM, CSF

Panel Additions

HBV genotype + drug resistance panel
Jak2 mutation, quantitative w/reflex to Exons 12-15 panel
Myeloma, FISH panel, tissue panel
Genetic result summary
- Genetic interpretation
- Genetic result table
- Genetic reason for referral
- Genetic specimen
- Genetic source
- Genetic tissue ID
- Genetic method
- Genetic disclaimer
- Genetic released by

Medications

Additions

CB-010 invest IV
IFx-Hu2.0 invest Intralesional
INCB057643 invest Oral
Olvimulogene Nanivacirepvec (Olvi-Vec) invest IV

Updates

Medication	Update
AZD5305 invest Oral	New Alias: Saruparib invest (AZD5305 invest Oral)
Tecentriq Hybreza (atezolizumab- hyaluronidase-tqjs Subcutaneous 1,875 mg-30,000 unit/15 mL)	New SIG: 1,875 mg subcutaneously every 3 weeks; administer over 7 minutes; administer in the thigh over approximately 7 minutes.
VET3-TFI invest Intratumoral	New Units: x 10e7 pfu x 10e8 pfu x 10e9 pfu Deactivated Units: e7 pfu e8 pfu e9 pfu
VET3-TGI invest IV	New Units: x 10e7 pfu x 10e8 pfu x 10e9 pfu Deactivated Units: e7 pfu e8 pfu e9 pfu

Regimen Library

Additions

Regimen Name	Diagnosis
Atezolizumab SQ Q21D	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ Q21D (Adjuvant NSCLC)	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ + Abraxane D1,8,15 + Carboplatin Q21D	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ + Bevacizumab Q21D	Hepatocellular Carcinoma (HCC)
Atezolizumab SQ + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 1 of 2: Induction)	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ + Bevacizumab + Paclitaxel + Carboplatin Q21D (Part 2 of 2: Atezolizumab SQ + Bevacizumab Maintenance)	Lung Cancer, Non-small Cell (NSCLC)
Atezolizumab SQ + Carboplatin + Etoposide D1-3 Q21D	Lung Cancer, Non-small Cell (NSCLC)
Influenza Vaccines 2024-2025	All Problems
Isatuximab-irfc + Carfilzomib D1,8,15 + Lenalidomide D1-21 + Dexamethasone Q28D	Multiple Myeloma (MM)
Isatuximab-irfc IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q42D (Part 2 of 2: Isatuximab-irfc IV + Lenalidomide + Dexamethasone Continuation Q28D, non-transplant candidates)	Multiple Myeloma (MM)
Pembrolizumab + Pemetrexed + Carboplatin Q21D (Mesothelioma)	Malignant Mesothelioma; Malignant Pleural Mesothelioma
Pembrolizumab + Pemetrexed + Cisplatin Q21D (Mesothelioma)	Malignant Mesothelioma; Malignant Pleural Mesothelioma
Tislelizumab-jsgr Q21D	Esophageal Cancer (Parent); Hepatocellular Carcinoma (HCC)
Vemurafenib + Cobimetinib Q28D fb Vemurafenib + Cobimetinib (Q28D) + Atezolizumab SQ (Q21D) Q84D (Part 1 of 2)	Melanoma, Skin
Vemurafenib + Cobimetinib Q28D fb Vemurafenib + Cobimetinib (Q28D) + Atezolizumab SQ (Q21D) Q84D (Part 2 of 2)	Melanoma, Skin
Venetoclax + Azacitidine D1-7 Q28D (AML)	Leukemia, Acute Myeloid (AML)
Venetoclax + Decitabine D1-5 Q28D (AML)	Leukemia, Acute Myeloid (AML)
Zoledronic acid (Zometa) Q28D (Hypercalcemia of Malignancy)	All Malignancies

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

All Problems
Esophageal Cancer (Parent)
Fallopian Tube Cancer
Gastric Cancer
Hemolytic Uremic Syndrome
Leukemia, Acute Myeloid (AML)
Lymphoma, Hodgkin (HL)
Lymphoma, Non-Hodgkin (NHL) (Parent)
Multiple Myeloma
Myasthenia Gravis
Myelodysplastic Syndrome (MDS)
Myelofibrosis
Myeloproliferative Disorder
Ovarian and Primary Peritoneal Cancer
Paroxysmal Nocturnal Hemoglobinuria
Polycythemia Vera
Thalassemia
Uterine Cancer (Parent)
Waldenstrom’s Macroglobulinemia

Renames

Previous Name	New Name
Isatuximab-irfc IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q42D	Isatuximab-irfc IV + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q42D (Part 1 of 2: Induction)
Venetoclax + Azacitidine D1-7 Q28D	Venetoclax + Azacitidine D1-7 Q28D (Myelofibrosis)
Venetoclax + Decitabine D1-5 Q28D	Venetoclax + Decitabine D1-5 Q28D (MDS, Myelofibrosis)

Removals

Regimen Name	Diagnosis
Atezolizumab + Abraxane D1,8 Q14D fb Atezolizumab + Doxorubicin + Cyclophosphamide (AC) Q14D Dose Dense	Breast Cancer
Atezolizumab Q21D (Adjuvant Breast)	Breast Cancer
Voxelotor Q30D	Anemia, Sickle Cell

Billing & HCPCS Codes

Updates

Medication	HCPCS Codes
Anthrax immune globulin (human) IV	J1599 per 60 units
Guselkumab IV	J1628 per 1 mg
Guselkumab Subcutaneous Pen Injector	J1628 per 1 mg
Influenza virus vaccine (PF) IM Tri-Split 65 yrs & older (High-Dose)	90662 per: 180 mcg 0.5 mL 1 EA
Ocrelizumab-hyaluronidase-ocsq Subcutaneous	J3590 per 23 mL
Palonosetron IV	J2469 per 0.025 mg
Pentamidine IV	J3490 per 300 mg

Appendix A

Problem & Code Summary

For the retired and replacement problems listed below, please follow steps 1-9 to update the patient records in the iKM Clinical Profile, problems area to support regimen management:

Locate the replacement problem in the second column
Chart the replacement problem in iKM Clinical Profile, Problems
Go to the patients flow sheet
Select the regimen
Select Edit regimen properties
Select drop-down for Associated problem, select the new replacement problem
Select Line of Therapy drop-down and select
Save
Document problem information (staging, biomarkers) in new problem

Retired Problem	Replacement Problem
Benign carcinoid tumor of left kidney	Well-differentiated neuroendocrine tumor of left kidney
Benign neoplasm of left female breast	Benign neoplasm of left breast
Benign neoplasm of right female breast	Benign neoplasm of right breast
Infiltrating ductal carcinoma of central portion of left female breast	Infiltrating duct carcinoma of central portion of left breast
Infiltrating ductal carcinoma of central portion of right female breast	Infiltrating duct carcinoma of central portion of right breast
Infiltrating ductal carcinoma of lower inner quadrant of left female breast	Infiltrating duct carcinoma of lower inner quadrant of left breast
Infiltrating ductal carcinoma of lower inner quadrant of right female breast	Infiltrating duct carcinoma of lower inner quadrant of right breast
Infiltrating ductal carcinoma of lower outer quadrant of left female breast	Infiltrating duct carcinoma of lower outer quadrant of left breast
Infiltrating ductal carcinoma of lower outer quadrant of right female breast	Infiltrating duct carcinoma of lower outer quadrant of right breast
Infiltrating ductal carcinoma of upper inner quadrant of left female breast	Infiltrating duct carcinoma of upper inner quadrant of left breast
Infiltrating ductal carcinoma of upper inner quadrant of right female breast	Infiltrating duct carcinoma of upper inner quadrant of right breast
Infiltrating ductal carcinoma of upper outer quadrant of left female breast	Infiltrating duct carcinoma of upper outer quadrant of left breast
Infiltrating ductal carcinoma of upper outer quadrant of right female breast	Infiltrating duct carcinoma of upper outer quadrant of right breast
Infiltrating lobular carcinoma of right female breast	Lobular carcinoma of right breast
Primary malignant neoplasm of bilateral female breasts	Primary malignant neoplasm of bilateral breasts
Recurrent primary malignant neoplasm of left female breast	Recurrent primary malignant neoplasm of left breast
Recurrent primary malignant neoplasm of right female breast	Recurrent primary malignant neoplasm of right breast

Additions

The following problem to ICD-10-CM mappings will be available in the Clinical Profile, Problems area of iKnowMed. The ICD-10-CM codes you see below are new as of Tuesday, Oct. 1, 2024.

Problem	ICD-10 Codes
Adverse reaction to drug	T45.AX5A Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, initial encounter T45.AX5D Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter T45.AX5S Adverse effect of immune checkpoint inhibitors and immunostimulant drugs, sequela
Aftercare	Z51.A Encounter for sepsis aftercare
Anal fistula	K60.30 Anal fistula, unspecified K60.311 Anal fistula, simple, initial K60.312 Anal fistula, simple, persistent K60.313 Anal fistula, simple, recurrent K60.319 Anal fistula, simple, unspecified K60.321 Anal fistula, complex, initial K60.322 Anal fistula, complex, persistent K60.323 Anal fistula, complex, recurrent K60.329 Anal fistula, complex, unspecified
Anaplastic large cell lymphoma, ALK negative	C84.7B Anaplastic large cell lymphoma, ALK-negative, in remission
Anaplastic lymphoma kinase positive anaplastic large cell lymphoma	C84.6A Anaplastic large cell lymphoma, ALK-positive, in remission
Angioimmunoblastic T-cell lymphoma	C86.41 Blastic NK-cell lymphoma, in remission C86.50 Angioimmunoblastic T-cell lymphoma not having achieved remission C86.51 Angioimmunoblastic T-cell lymphoma, in remission
Anorectal fistula	K60.50 Anorectal fistula, unspecified K60.511 Anorectal fistula, simple, initial K60.512 Anorectal fistula, simple, persistent K60.513 Anorectal fistula, simple, recurrent K60.519 Anorectal fistula, simple, unspecified K60.521 Anorectal fistula, complex, initial K60.522 Anorectal fistula, complex, persistent K60.523 Anorectal fistula, complex, recurrent K60.529 Anorectal fistula, complex, unspecified
Anosognosia	R41.85 Anosognosia
B-cell lymphoma	C85.1A Unspecified B-cell lymphoma, in remission
Bicuspid aortic valve	Q23.81 Bicuspid aortic valve
Blastic plasmacytoid dendritic cell neoplasm	C86.40 Blastic NK-cell lymphoma not having achieved remission
Burkitt’s lymphoma (clinical)	C83.7A Burkitt lymphoma, in remission
Carcinoid heart disease	E34.01 Carcinoid heart syndrome
Carcinoid syndrome	E34.00 Carcinoid syndrome, unspecified E34.09 Other carcinoid syndrome
Central centrifugal cicatricial alopecia	L66.81 Central centrifugal cicatricial alopecia
Childhood obesity	Z68.55 Body mass index [BMI] pediatric, 120% of the 95th percentile for age to less than 140% of the 95th percentile for age Z68.56 Body mass index [BMI] pediatric, greater than or equal to 140% of the 95th percentile for age
Cholestatic pruritus	L29.81, Cholestatic pruritus
Cleft leaflet of mitral valve	Q23.82 Congenital mitral valve cleft leaflet
Congenital anomaly of aortic valve Congenital anomaly of mitral valve	Q23.88 Other congenital malformations of aortic and mitral valves
Degeneration of lumbar intervertebral disc	M51.360 Other intervertebral disc degeneration, lumbar region with discogenic back pain only M51.361 Other intervertebral disc degeneration, lumbar region with lower extremity pain only M51.362 Other intervertebral disc degeneration, lumbar region with discogenic back pain and lower extremity pain M51.369 Other intervertebral disc degeneration, lumbar region without mention of lumbar back pain or lower extremity pain
Degeneration of lumbosacral intervertebral disc	M51.370 Other intervertebral disc degeneration, lumbosacral region with discogenic back pain only M51.371 Other intervertebral disc degeneration, lumbosacral region with lower extremity pain only M51.372 Other intervertebral disc degeneration, lumbosacral region with discogenic back pain and lower extremity pain M51.379 Other intervertebral disc degeneration, lumbosacral region without mention of lumbar back pain or lower extremity pain
Dehiscence of surgical wound	T81.321A Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, initial encounter T81.321D Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, subsequent encounter T81.321S Disruption or dehiscence of closure of internal operation (surgical) wound of abdominal wall muscle or fascia, sequela T81.328A Disruption or dehiscence of closure of other specified internal operation (surgical) wound, initial encounter T81.328D Disruption or dehiscence of closure of other specified internal operation (surgical) wound, subsequent encounter T81.328S Disruption or dehiscence of closure of other specified internal operation (surgical) wound, sequela T81.329A Deep disruption or dehiscence of operation wound, unspecified, initial encounter T81.329D Deep disruption or dehiscence of operation wound, unspecified, subsequent encounter T81.329S Deep disruption or dehiscence of operation wound, unspecified, sequela
Diffuse follicle center lymphoma	C82.5A Diffuse follicle center lymphoma, in remission
Diffuse large B-cell lymphoma	C83.398 Diffuse large B-cell lymphoma of other extranodal and solid organ sites C83.3A Diffuse large B-cell lymphoma, in remission
Diffuse non-Hodgkin’s lymphoma	C83.8A Other non-follicular lymphoma, in remission C83.9A Non-follicular (diffuse) lymphoma, unspecified, in remission
Disorder of carbohydrate metabolism	E74.829 Other disorders of citrate metabolism
Disorder of carbohydrate transport	E74.820 SLC13A5 Citrate Transporter Disorder
Disorder of skeletal muscle	M62.85 Dysfunction of the multifidus muscles, lumbar region
Edema	R60.0 – Localized edema R60.1 – Generalized edema R60.9 – Edema, unspecified
Enteropathy-associated T-cell lymphoma	C86.20 Enteropathy-type (intestinal) T-cell lymphoma not having achieved remission
Enteropathy-type (intestinal) T-cell	C86.21 Enteropathy-type (intestinal) T-cell lymphoma, in remission
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma)	C88.40 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT- lymphoma] not having achieved remission C88.41 Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT- lymphoma], in remission
Extranodal NK/T-cell lymphoma, nasal type	C85.9A Non-Hodgkin lymphoma, unspecified, in remission C86.00 Extranodal NK/T-cell lymphoma, nasal type not having achieved remission C86.01 Extranodal NK/T-cell lymphoma, nasal type, in remission
Family history of familial multiple	Z83.72 Family history of familial adenomatous polyposis
Fanconi’s anemia	D61.03 Fanconi anemia
Finding of receipt of benefit status	Z59.72 Insufficient welfare support
Finding related to health insurance issues	Z59.71 Insufficient health insurance coverage
Follicular lymphoma	C82.8A Other types of follicular lymphoma, in remission C82.9A Follicular lymphoma, unspecified, in remission
Follicular lymphoma grade 3a	C82.3A Follicular lymphoma grade IIIa, in remission
Follicular lymphoma grade 3b	C82.4A Follicular lymphoma grade IIIb, in remission
Follicular non-Hodgkin’s lymphoma, large cell	C82.2A, Follicular lymphoma grade III, unspecified, in remission
Follicular non-Hodgkin’s lymphoma, mixed small, cleaved cell and large cell (disorder)	C82.1A Follicular lymphoma grade II, in remission
Follicular non-Hodgkin’s lymphoma, small, cleaved cell (clinical)	C82.0A Follicular lymphoma grade I, in remission
Frontal fibrosing alopecia	L66.12 Frontal fibrosing alopecia
Fy(a-b-) phenotype	Z67.A1 Duffy null
Fy(a-b+) phenotype	Z67.A3 Duffy b positive
Fy(a+b-) phenotype	Z67.A2 Duffy a positive
Fy(a+b+) phenotype	Z67.A4 Duffy a and b positive
Gastrointestinal anastomotic dehiscence	T81.320A Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, initial encounter T81.320D Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, subsequent encounter T81.320S Disruption or dehiscence of gastrointestinal tract anastomosis, repair, or closure, sequela
Genetic susceptibility to genetic disorder	Z15.1 Genetic susceptibility to epilepsy and neurodevelopmental disorders Z15.2 Genetic susceptibility to obesity
Heavy chain disease	C88.20 Heavy chain disease not having achieved remission C88.21 Heavy chain disease, in remission
Hepatosplenic T-cell lymphoma	C86.10 Hepatosplenic T-cell lymphoma not having achieved remission C86.11 Hepatosplenic T-cell lymphoma, in remission
History of adenomatous polyp of colon	Z86.0101 Personal history of adenomatous and serrated colon polyps Z86.0102 Personal history of hyperplastic colon polyps
History of drug therapy	Z92.26 Personal history of immune checkpoint inhibitor therapy
History of polyp of colon	Z86.0100 Personal history of colon polyps, unspecified Z86.0109, Personal history of other colon polyps
Hodgkin lymphoma lymphocytic depletion	C81.3A Lymphocyte depleted Hodgkin lymphoma, in remission
Hodgkin’s disease in remission	C81.7A Other Hodgkin lymphoma, in remission C81.9A Hodgkin lymphoma, unspecified, in remission
Hodgkin’s disease, nodular sclerosis	C81.0A Nodular lymphocyte predominant Hodgkin lymphoma, in remission C81.1A Nodular sclerosis Hodgkin lymphoma, in remission
Hormone receptor negative neoplasm	Z17.420 Hormone receptor negative with human epidermal growth factor receptor 2 positive status Z17.421 Hormone receptor negative with human epidermal growth factor receptor 2 negative status
Hormone receptor positive tumor	Z17.410 Hormone receptor positive with human epidermal growth factor receptor 2 positive status Z17.411 Hormone receptor positive with human epidermal growth factor receptor 2 negative status
Human epidermal growth factor 2 gene amplification not detected	Z17.32 Human epidermal growth factor receptor 2 negative status
Human epidermal growth factor receptor 2 gene amplification detected	Z17.31 Human epidermal growth factor receptor 2 positive status
Hypoglycemia	E16.A1 Hypoglycemia level 1 E16.A2 Hypoglycemia level 2 E16.A3 Hypoglycemia level 3
Immunoproliferative small intestinal disease (clinical)	C88.30 Immunoproliferative small intestinal disease not having achieved remission C88.31 Immunoproliferative small intestinal disease, in remission
Intentional poisoning by drug	T45.AX3A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, initial encounter T45.AX3D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, subsequent encounter T45.AX3S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, assault, sequela
Intentional self-poisoning	T45.AX2A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, initial encounter T45.AX2D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, subsequent encounter T45.AX2S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, intentional self-harm, sequela
Itching of skin	L29.89 Other pruritus
Kleefstra syndrome	Q87.86 Kleefstra syndrome
Lichen planopilaris	L66.10 Lichen planopilaris, unspecified L66.11 Classic lichen planopilaris L66.19 Other lichen planopilaris
Lymphocyte-rich classical Hodgkin lymphoma	C81.4A Lymphocyte-rich Hodgkin lymphoma, in remission
Malignant immunoproliferative disease (clinical)	C88.80 Other malignant immunoproliferative diseases not having achieved remission C88.81 Other malignant immunoproliferative diseases, in remission C88.90 Malignant immunoproliferative disease, unspecified not having achieved remission C88.91 Malignant immunoproliferative disease, unspecified, in remission
Malignant lymphoma – small lymphocytic	C83.0A Small cell B-cell lymphoma, in remission
Mantle cell lymphoma	C83.1A Mantle cell lymphoma, in remission
Mature T-cell AND/OR NK cell neoplasm	C84.9A Mature T/NK-cell lymphomas, unspecified, in remission C84.ZA Other mature T/NK-cell lymphomas, in remission
Mixed cellularity Hodgkins lymphoma	C81.2A Mixed cellularity Hodgkin lymphoma, in remission
Mycosis fungoides (clinical)	C84.0A Mycosis fungoides, in remission
Non-Hodgkin’s lymphoma in remission	C85.8A Other specified types of non-Hodgkin lymphoma, in remission
Obese class I	E66.811 Obesity, class 1
Obesity	E66.89 Other obesity not elsewhere classified
Obesity, class II	E66.812 Obesity, class 2
Obesity, class III	E66.813 Obesity, class 3
Peripheral T-cell lymphoma (clinical)	C84.4A Peripheral T-cell lymphoma, not elsewhere classified, in remission
Poisoning by drug AND/OR medicinal substance	T45.AX1A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), initial encounter T45.AX1D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), subsequent encounter T45.AX1S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, accidental (unintentional), sequela T45.AX4A Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, initial encounter T45.AX4D Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, subsequent encounter T45.AX4S Poisoning by immune checkpoint inhibitors and immunostimulant drugs, undetermined, sequela
Precursor cell lymphoblastic lymphoma	C83.5A Lymphoblastic (diffuse) lymphoma, in remission
Presymptomatic type 1 diabetes mellitus	E10.A0 Type 1 diabetes mellitus, presymptomatic, unspecified E10.A1 Type 1 diabetes mellitus, presymptomatic, Stage 1 E10.A2 Type 1 diabetes mellitus, presymptomatic, Stage 2
Primary central nervous system lymphoma	C83.390 Primary central nervous system lymphoma
Primary cutaneous CD30+ large T-cell lymphoma	C86.60 Primary cutaneous CD30-positive T-cell proliferations not having achieved remission C86.61 Primary cutaneous CD30-positive T-cell proliferations, in remission
Primary cutaneous follicular center B-cell lymphoma	C82.6A Cutaneous follicle center lymphoma, in remission
Primary cutaneous T-cell lymphoma	C84.AA Cutaneous T-cell lymphoma, unspecified, in remission
Primary mediastinal (thymic) large B-cell lymphoma	C85.2A Mediastinal (thymic) large B-cell lymphoma, in remission
Progesterone receptor negative neoplasm	Z17.22 Progesterone receptor negative status
Progesterone receptor positive tumor	Z17.21 Progesterone receptor positive status
Pulmonary embolism	I26.03 Cement embolism of pulmonary artery with acute cor pulmonale I26.95 Cement embolism of pulmonary artery without acute cor pulmonale
Pulmonary fat embolism	I26.04 Fat embolism of pulmonary artery with acute cor pulmonale I26.96 Fat embolism of pulmonary artery without acute cor pulmonale
Rectal fistula	K60.40 Rectal fistula, unspecified K60.411 Rectal fistula, simple, initial K60.412 Rectal fistula, simple, persistent K60.413 Rectal fistula, simple, recurrent K60.419 Rectal fistula, simple, unspecified K60.421 Rectal fistula, complex, initial K60.422 Rectal fistula, complex, persistent K60.423 Rectal fistula, complex, recurrent K60.429 Rectal fistula, complex, unspecified
Scarring alopecia	L66.89 Other cicatricial alopecia
Sezary’s disease	C84.1A Sezary disease, in remission
Stenosis of nasal valve	J34.8200 Internal nasal valve collapse, unspecified J34.8201 Internal nasal valve collapse, static J34.8202 Internal nasal valve collapse, dynamic J34.8210 External nasal valve collapse, unspecified J34.8211 External nasal valve collapse, static J34.8212 External nasal valve collapse, dynamic J34.829 Nasal valve collapse, unspecified
Subcutaneous panniculitis-like T-cell lymphoma	C86.30 Subcutaneous panniculitis-like T-cell lymphoma not having achieved remission C86.31 Subcutaneous panniculitis-like T-cell lymphoma, in remission
Synovitis and tenosynovitis	M65.90 Unspecified synovitis and tenosynovitis, unspecified site M65.921 Unspecified synovitis and tenosynovitis, right upper arm M65.922 Unspecified synovitis and tenosynovitis, left upper arm M65.929 Unspecified synovitis and tenosynovitis, unspecified upper arm M65.931 Unspecified synovitis and tenosynovitis, right forearm M65.932 Unspecified synovitis and tenosynovitis, left forearm M65.939 Unspecified synovitis and tenosynovitis, unspecified forearm M65.951 Unspecified synovitis and tenosynovitis, right thigh M65.952 Unspecified synovitis and tenosynovitis, left thigh M65.959 Unspecified synovitis and tenosynovitis, unspecified thigh M65.961 Unspecified synovitis and tenosynovitis, right lower leg M65.962 Unspecified synovitis and tenosynovitis, left lower leg M65.969 Unspecified synovitis and tenosynovitis, unspecified lower leg M65.98 Unspecified synovitis and tenosynovitis, other site
Synovitis and tenosynovitis of joint of hand	M65.941 Unspecified synovitis and tenosynovitis, right hand M65.942 Unspecified synovitis and tenosynovitis, left hand M65.949 Unspecified synovitis and tenosynovitis, unspecified hand
Synovitis and tenosynovitis of multiple joints	M65.99 Unspecified synovitis and tenosynovitis, multiple sites
Synovitis of left ankle joint Synovitis of joint of left foot Tenosynovitis of left ankle Tenosynovitis of left foot	M65.972 Unspecified synovitis and tenosynovitis, left ankle and foot
Synovitis of right ankle joint Synovitis of joint of right foot Tenosynovitis of right ankle Tenosynovitis of right foot	M65.971 Unspecified synovitis and tenosynovitis, right ankle and foot
Synovitis/tenosynovitis – shoulder	M65.911 Unspecified synovitis and tenosynovitis, right shoulder M65.912 Unspecified synovitis and tenosynovitis, left shoulder M65.919 Unspecified synovitis and tenosynovitis, unspecified shoulder
Tenosynovitis of ankle Tenosynovitis of foot Synovitis of ankle joint Synovitis of joint of foot	M65.979 Unspecified synovitis and tenosynovitis, unspecified ankle and foot
Uses less medication than prescribed	T45.AX6A Underdosing of immune checkpoint inhibitors and immunostimulant drugs, initial encounter T45.AX6D Underdosing of immune checkpoint inhibitors and immunostimulant drugs, subsequent encounter T45.AX6S Underdosing of immune checkpoint inhibitors and immunostimulant drugs, sequela
Waldenström macroglobulinemia	C88.00 Waldenstrom macroglobulinemia not having achieved remission C88.01 Waldenstrom macroglobulinemia, in remission